Skip to main content
    S

    Sera Prognostics Inc (SERA)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $2.04
    -0.03 (-1.45%)

    Market Cap: $81.66M

    Last updated: Oct 16, 2026 at 4:57 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    68%(15/22)
    Avg Surprise
    -4.22%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.14
    Range$-0.18 - $-0.10
    4 analysts
    EPS Revisions
    2
    0
    7d
    2
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.17+17.6%
    60d ago$-0.17+16.0%
    30d ago$-0.17+16.0%
    7d ago$-0.18+22.2%
    Current$-0.14
    Revenue Consensus
    $75000
    Range$0 - $100000
    4 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.18
    Range$-0.25 - $-0.15
    4 analysts
    Revenue Consensus
    $33330
    Range$-91670 - $108330
    4 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.18---
    Sep 26EST
    		-$-0.14---
    Jun 26
    Reported Aug 12
    		$-0.18$-0.14-28.57%Miss-12.5%
    Mar 26
    Reported May 6
    		$-0.17$-0.17+0.00%Beat+15.0%
    Dec 25
    Reported Mar 18
    		$-0.16$-0.19+13.70%Beat+36.0%
    Sep 25
    Reported Nov 13
    		$-0.16$-0.21+23.81%Beat+33.3%
    Jun 25
    Reported Aug 6
    		$-0.16$-0.24+33.33%Beat+36.0%
    Mar 25
    Reported May 7
    		$-0.20$-0.21+4.76%Beat+20.0%
    Dec 24
    Reported Mar 19
    		$-0.25$-0.23-8.70%Miss+0.0%
    Sep 24
    Reported Nov 6
    		$-0.24$-0.22-9.09%Miss-4.3%
    Jun 24
    Reported Aug 7
    		$-0.25$-0.26+3.85%Beat+26.5%
    Mar 24
    Reported May 8
    		$-0.25$-0.27+7.41%Beat+26.5%
    Dec 23
    Reported Mar 20
    		$-0.25$-0.26+3.85%Beat+19.4%
    Sep 23
    Reported Nov 8
    		$-0.23$-0.35+34.29%Beat+34.3%
    Jun 23
    Reported Aug 9
    		$-0.34$-0.36+5.56%Beat+8.1%
    Mar 23
    Reported May 10
    		$-0.34$-0.38+10.53%Beat+15.0%
    Dec 22
    Reported Mar 22
    		$-0.31$-0.37+16.22%Beat+24.4%
    Sep 22
    Reported Nov 9
    		$-0.35$-0.62+43.55%Beat+10.3%
    Jun 22
    Reported Aug 10
    		$-0.37$-0.41+9.76%Beat+88.3%
    Mar 22
    Reported May 10
    		$-0.40$-0.37-8.11%Miss-135.3%
    Dec 21
    Reported Mar 29
    		$-0.41$-0.29-41.38%Miss+76.0%
    Sep 21
    Reported Nov 9
    		$-0.39$-0.25-56.00%Miss+73.7%
    Jun 21
    Reported Jul 16
    		$-3.17$-1.26-151.59%Miss-
    Mar 21
    Reported Jun 2
    		$-0.17$-0.17+0.00%Beat-
    Dec 20
    Reported Mar 31
    		$-1.71$0.00N/AMiss-
    Dec 19
    Reported Mar 30
    		$-1.48$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-3.04EV/EBITDAN/A
    Price/FCF-3.66xFCF Yield-27.34%
    Profitability
    Profit Margin0.00%Operating Margin-33347.00%
    ROE-45.00%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest Coverage-4746.57x
    Current Ratio1.98xQuick Ratio1.98x
    Trading Statistics
    Beta1.06Avg Volume15.66K
    52-Week High$3.9552-Week Low$1.56

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$2.05
    SMA 20$2.06
    SMA 50$2.04
    SMA 200$2.21
    EMA 10$2.05
    EMA 20$2.05
    EMA 50$2.05
    EMA 200$2.22

    MACD

    Line: -0.00Signal: 0.00Hist: -0.00

    ADX

    ADX: 19.7+DI: 22.7-DI: 10.1

    Aroon & PSAR

    Aroon Up88.0
    Aroon Down20.0
    PSAR$2.01

    Bollinger Bands

    Upper Band$2.13
    Lower Band$1.98
    %B Position723%(Upper)
    Band Width0.37

    RSI (14-Day)

    Neutral
    49.1

    Momentum Oscillators

    Stoch %K23.8
    Stoch %D21.9
    Williams %R-81.0
    ROC (10d)1.5%
    Momentum0.03
    CCI (20d)-71.2
    MFI (14d)55.4

    Volatility Measures

    ATR (14d)$0.09(4.6%)
    StdDev (20d)0.04
    Hist Vol37.3%(Moderate)

    Volume Flow

    VWAP$2.04
    OBV5.9M
    AD Line3.8M
    CMF (20d)-0.474

    Volume Metrics

    Avg Vol (20d)14.4K
    Vol Ratio0.3x(Low)
    VWMA (20d)$2.07

    Pivot Points

    R3$2.17
    R2$2.14
    R1$2.10
    Pivot Point$2.07
    S1$2.03
    S2$2.00
    S3$1.96

    Advanced Oscillators

    TSI-0.16
    Ultimate Osc30.4
    KST5.15

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$30,000$14,000$10,000$16,000$17,000$38,000$24,000$29,000$24,000$0$41,000$42,000
    Cost of Revenue$0$0$42,000$0$0$0$32,000$0$0$0$236,000$0
    Gross Profit$30,000$14,000$10,000$16,000$17,000$38,000$24,000$29,000$24,000$0$41,000$42,000
    Operating Expenses$10.03M$9.33M$8.92M$8.96M$9.34M$9.25M$9.41M$8.88M$9.26M$9.08M$8.87M$8.18M
    R&D$3.49M$3.03M$3.22M$3.28M$3.34M$3.33M$3.14M$3.50M$4.41M$3.68M$3.90M$3.54M
    SG&A$4.25M$4.29M$4.04M$4.08M$4.14M$4.44M$4.01M$4.20M$3.75M$4.17M$3.67M$3.29M
    Operating Income$-10,004,000$-9,360,000$-8,954,000$-8,980,000$-9,320,000$-9,250,000$-9,423,000$-8,862,000$-9,253,000$-9,097,000$-8,848,000$-8,184,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$2,000$2,000$1,000$2,000$2,000$4,000$6,000$5,000$8,000$9,000$11,000$14,000
    Income Before Tax$-9,139,000$-8,399,000$-7,881,000$-7,814,000$-8,046,000$-8,187,000$-8,579,000$-7,919,000$-8,303,000$-8,097,000$-7,925,000$-7,210,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-9,139,000$-8,399,000$-7,881,000$-7,814,000$-8,046,000$-8,187,000$-8,579,000$-7,919,000$-8,303,000$-8,097,000$-7,925,000$-7,210,000
    EBITDA$-8,888,000$-8,137,000$-7,570,000$-7,444,000$-7,655,000$-7,818,000$-8,216,000$-7,570,000$-7,947,000$-7,737,000$-7,567,000$-6,848,000
    EBIT$-9,137,000$-8,397,000$-7,880,000$-7,812,000$-8,044,000$-8,183,000$-8,573,000$-7,914,000$-8,295,000$-8,088,000$-7,914,000$-7,196,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about SERA

    News

    Sera prognostics CMO Inglis sells $16,288 in shares By Investing.com

    Tiffany Eul Davis Inglis, Chief Medical Officer of SERA PROGNOSTICS, INC. (NASDAQ:SERA), sold 8,024 shares totaling $16,288 on October 12, 2026. This was a "sell to cover" transaction for tax obligations...

    Investing.com UK•10/13/26•Somewhat-Bearish

    An officer’s 8,024-share sale at Sera Prognostics (SERA) was required to cover taxes, not discretionary.

    Sera Prognostics officer Tiffany Inglis sold 8,024 Class A common shares on October 12, 2026, to cover tax withholding obligations related to restricted stock unit vesting. This transaction was mandated by the issuer...

    Stock Titan•10/13/26•Neutral

    Tiffany Inglis, Sera Prognostics CMO, sells $972 in shares By Investing.com

    Tiffany Inglis, CMO at Sera Prognostics, sold 486 shares worth $972 to cover tax withholding obligations related to restricted stock units. This "sell to cover" transaction was mandatory...

    Investing.com Australia•9/11/26•Somewhat-Bearish

    Sera prognostics CCO Lee Jr. sells $3,600 in stock

    Dyaarl Lee Jr., CCO at SERA PROGNOSTICS, INC. (NASDAQ:SERA), sold 1,800 shares of Class A Common Stock for $3,600 on September 10...

    Investing.com•9/11/26•Somewhat-Bearish

    Tiffany Inglis, Sera Prognostics CMO, sells $972 in shares

    Tiffany Inglis, Chief Medical Officer at Sera Prognostics, Inc. (SERA), sold 486 shares of the company's Class A Common Stock for a total of $972. This transaction was a mandatory "sell to cover" to meet tax withholding...

    Investing.com•9/11/26•Somewhat-Bearish

    SERA Valuation and Fair Value

    P/E
    -3.0x
    P/FCF
    -3.7x
    P/B
    1.7x
    See GNG's fair value

    SERA Profitability: Margins, ROIC and FCF

    Gross margin
    100.0%
    Operating margin
    -33347.0%
    Net margin
    0.0%
    ROE
    -45.0%
    FCF yield
    -27.3%

    SERA Competitors

    CompanyTicker
    CareCloud, Inc.CCLD
    Neumora Therapeutics, Inc.NMRA
    Equillium IncEQ
    NeOnc Technologies Holdings, Inc. Common StockNTHI
    Hyperfine IncHYPR
    Cardiff Oncology IncCRDF
    OnKure Therapeutics, Inc.OKUR
    Lixte Biotechnology Holdings IncLIXT

    Sector: Healthcare

    SERA Analyst Ratings

    Consensus
    Buy
    Analysts
    4
    Strong Buy
    0
    Buy
    4
    Hold
    0
    Sell
    0
    Strong Sell
    0

    SERA Bull Case vs Bear Case

    Bull case

    • SERA grew quarterly revenue 76.5% year over year.

    SERA Earnings: Beat Rate and Next Report

    Beat rate
    4 of 8 quarters (50.0%)
    Average surprise
    3.7%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.14
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    2 up, 0 down

    Frequently Asked Questions About SERA

    Does SERA pay dividends?

    Sera Prognostics Inc (SERA) does not currently pay a regular dividend.

    What is SERA's market cap?

    Sera Prognostics Inc (SERA) has a market capitalization of $81.66M with a current stock price of $2.04.

    Related stocks

    Sector: Healthcare

    All stocks starting with S

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In